Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Sees Large Drop in Short Interest

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 29,300 shares, a drop of 60.9% from the January 31st total of 74,900 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily volume of 332,300 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on CMMB shares. Maxim Group upped their price target on shares of Chemomab Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. Oppenheimer reiterated an “outperform” rating and set a $11.00 price target (down previously from $13.00) on shares of Chemomab Therapeutics in a report on Friday, November 15th.

Institutional Trading of Chemomab Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CMMB. Sphera Funds Management LTD. purchased a new position in Chemomab Therapeutics during the 3rd quarter valued at about $1,907,000. XTX Topco Ltd grew its stake in Chemomab Therapeutics by 63.8% in the fourth quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock worth $45,000 after purchasing an additional 9,706 shares during the period. Finally, Virtu Financial LLC purchased a new position in Chemomab Therapeutics during the fourth quarter valued at $26,000. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Stock Up 3.4 %

Shares of CMMB stock traded up $0.06 on Friday, reaching $1.68. The company’s stock had a trading volume of 9,714 shares, compared to its average volume of 489,108. Chemomab Therapeutics has a 12-month low of $0.58 and a 12-month high of $2.55. The company has a market capitalization of $24.05 million, a P/E ratio of -1.68 and a beta of 0.66. The stock’s 50 day simple moving average is $1.97 and its 200-day simple moving average is $1.73.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).